The Assessment of Effect of Sacubitril/Valsartan Combination in Patients with Heart Failure and Reduced Ejection Fraction: A Single Center Study
DOI:
https://doi.org/10.52783/jns.v14.2166Keywords:
sacubitril/valsartan, ARNi, Heart failure with reduced ejection fraction, Clinical pharmacistAbstract
Background: sacubitril/valsartan approved in 2015 to use in heart failure patients with reduced ejection fraction and dramatic results gained, the effects of it in heart failure patients is assessed by many clinical parameters.
Aims: Assessment the role of sacubitril/valsartan combination as Angiotensin Receptor Neprilysin Inhibitor in heart failure patients in AL Nasiriyaha Heart Centre-Iraq by explain the dramatic effect of sacubitril/valsartan in improve the clinical state of patients.
Patients and Methods: This is interventional study that included 73 patients with heart failure patients and reduced ejection fraction who visited the cardiac outpatient clinic in AL Nasiriyaha Heart Centre Thi-Qar Iraq who received Sacubitril/Valsartan as Angiotensin Receptor Neprilysin Inhibitor, study period was two months.
Results: This study explained the role of sacubitril/valsartan combination in improve clinical states of patients by follow-up the sample from heart failure and reduced ejection fraction patients.
Conclusions: Sacubitril and Valsartan demonstrated clinical efficacy in treatments of heart failure patients with reduced ejection fraction in the Nasiriyah Heart Center, Thi-Qar province, by improving vital signs related to disease.
Downloads
Metrics
References
Zhang R, Sun X, Li Y, He W, Zhu H, Liu B, Zhang A. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec: 27: 10742484211058681. doi: 10.1177/10742484211058681.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11): 993-1004. doi: 10.1056/NEJMoa1409077.
Judge PK. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III - Rationale, trial design and baseline data. Nephrology Dialysis Transplantation. 2017; 32(12): 2043–2051. doi: 10.1093/ndt/gfw321.
Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2020 Jan; 8(1): 43-54. doi: 10.1016/j.jchf.2019.08.003.
Veltri KT. Novel Agent, Sacubitril-Valsartan: Prescribing Patterns and Perceived Barriers to Hospital Formulary Inclusion. Clinical Studies & Medical Case Reports. 2019; 6(1): 1-7. https://doi.org/10.24966/csmc-8801/100062
Patil T. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF). Journal of Cardiovascular Translational Research. 2022; 15(6): 1424–1435. https://doi.org/10.1007/s12265-022-10262-9.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ,. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 45(18). https://doi.org/10.1161/CIR.0000000000001063.
Ntalianis A. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews. 2022; 27(1): 1-13. https://doi.org/10.1007/s10741-021-10115-8.
Buda V. An Up-to Date Article Regarding Particularities Drug Treatment in Patients with Chronic Heart Failure. Journal of Clinical Medicine. 2022; 11(7). https://doi.org/10.3390/jcm11072020
Hu T, Liu Y. Lou Y. Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis. Frontiers in Pharmacology. 2023; 14. https://doi.org/10.3389/fphar.2023.925375
Al-Ganmi AHA, Al-Fayyadh, S, Ali A, Alotaibi AM, Gholizadeh L, Perry L. Medication adherence and predictive factors in patients with cardiovascular disease: A comparison study between Australia and Iraq. Nurs Health Sci. 2020 Jun; 22(2): 454-463. doi: 10.1111/nhs.12681.
Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal Effects and Associated Outcomes during Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 Jun; 6(6): 489-498. doi: 10.1016/j.jchf.2018.02.004.
Regitz-Zagrosek V. Sex and Gender Differences in Heart Failure. International Journal of Heart Failure. 2020; 2(3): 157-181. https://doi.org/10.36628/ijhf.2020.0004.
El-Battrawy I. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus. ESC Heart Failure. 2023; 10(2): 943-954. https://doi.org/10.1002/ehf2.14239.
Egan TD, Orgain N. Cigarette Smoking Cessation. Essence of Anesthesia Practice E-Book. 2010; 86. https://doi.org/10.1016/B978-1-4377-1720-4.00076-5.
Hafizullah M, Aman W, Afridi H. Evaluation of Angiotensin Receptor and Neprlysin Inhibition (Arni) in Patients of Heart Failure With Reduced Ejection Fraction (Hfref) - a Real-World Study. Pakistan Heart Journal. 2023; 56(1): 22–27. https://doi.org/10.47144/phj.v56i1.2454.
Ganesananthan S. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart. 2020; 7(2). https://doi.org/10.1136/openhrt-2020-001305.
Bayard G, Da Costa A, Pierrard R, Roméyer-Bouchard C, Guichard JB, Isaaz K. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019 Sep 3:25: 100418. doi: 10.1016/j.ijcha.2019.100418.
Almufleh A. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. American journal of cardiovascular disease. 2017; 7(6): 108–113.
Vardeny O. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. European Journal of Heart Failure. 2019; 21(3): 337–341. https://doi.org/10.1002/ejhf.1402.
Kim HJ. Cardiac and kidney outcomes after sacubitril-valsartan therapy: recovery of cardiac function relative to kidney function decline. Kidney Research and Clinical Practice. 2024; 43(5): 614-625. https://doi.org/10.23876/j.krcp.24.021.
Arslan A. The Relationship between CRP to Albumin Ratio and Non Ischemic Cardiomyopathy in Atrial Fibrillation Patients. Research square. 2024; 1-18. https://doi.org/10.21203/rs.3.rs-5456454/v1.
Usuda D. Angiotensin receptor blocker neprilysin inhibitors. World Journal of Cardiology. Baishideng Publishing Group Inc. 2021; 325–339. https://doi.org/10.4330/wjc.v13.i8.325.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
